Dublin, 10 March 2021 (GLOBE NEWSWIRE) – Added report “Homozygous Familial Hypercholesterolemia – Epidemiology Forecast to 2030” ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, the family epidemiology of Homozygous hypercholesterolemia (HoFH) in the United States, EU5 (Germany, Spain, Italy, France and the United Kingdom) and Japan.
The epilepsy covered in the report provides a historical epidemiology as well as a predicted segregation of Prevalence of Homozygous Familial Hypercholesterolemia (HoFH), Prevalence Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) and Mutation Distribution specific of Homozygous Familial Hypercholester. covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
Homozygous Famalial Hypercholesterolemia (HoFH) Detailed Epidemiology Segmentation
- The average population of HoFH in the seven major markets is estimated at 3,882 in 2020.
- The estimated confirmed cases of HoFH, in the United States are estimated at 698 in 2020.
- HoFH can be divided into LDL Receptor (LDLR), Apolipoprotein B (Apo B), Proprotein Convertase Subtilin / Kexin 9 (PCSK9), and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene) based on the types of mutations causing the condition. In the United States, the number of HoFH cases caused by LDLR, Apo B, PCSK9, and other rare mutations (SREBP2 genes, and STAP1, LDLRAP1 gene) was 587, 20, 13, and 33 respectively, in in 2017.
- In EU5 countries, the frequency of HoFH detected was highest in Germany with 231 cases, followed by France with 189 cases in 2017. While, the lowest number of cases in the Spain, with 131 cases in 2017.
- In Japan, the frequency of HoFH is estimated at 215 in 2020.
Scope of the report
- The report covers the descriptive view of Homozygous Familial Hypercholesterolemia (HoFH), explaining its causes, signs and symptoms, pathophysiology.
- The report gives us an overview of the historical and projected 7MM patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan .
- The report assesses the risk and burden of disease and clarifies the unmet needs of Homozygous Familial Hypercholesterolemia (HoFH).
- The report provides the epidemiological segregation of the disease for the 7MM by Frequency of Homozygous Familial Hypercholesterolemia (HoFH), Prevalence Diagnosis of Homozygous Familial Hypercholesterolemia (HoFH) and Circulation of Homozygous Familial Hypercholesterolemia (HoFH).
Report the top events
- Eleven Year Estimate of Homozygous Familial Hypercholesterolemia (HoFH)
- Cover 7MM
- The publisher has also analyzed specific data on HoFH, which suggested that mutations in the LDLR gene are the most common causes of HoFH compared to Apo B, PCSK9, and other rare mutations (SREBP2, and STAP1 gene, LDLRAP1 gene).
Key questions answered
- What is the risk of disease, burden and unmet needs of Familial Hypercholesterolemia (HoFH)?
- What is the historical patient pool of Homozygous Familial Hypercholesterolemia (HoFH) in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the prognosis in patients of Homozygous Familial Hypercholesterolemia (HoFH) at 7MM level?
- What are the growth opportunities across the 7MM in terms of the number of patients with Hypertcholesterolemia Famozial Familial Hypercholesterolemia (HoFH)?
- Out of the above countries, which country had the highest population of Homozygous Hypercholesterolemia Familial Hypercholesterolemia (HoFH) during the expected period (2020-2030)?
- What CAGR is the population expected to grow over the 7MM in the projected period (2020-2030)?
Key Assessments
- Patient separation
- Danger of disease and cattle
- Disease risk with separation
- Factors driving growth in a particular patient population
Key topics covered:
1 Key Views
2 Executive Summary
3 A Look at Homozygous Familial Hypercholesterolemia (HOFH)
4 Disease Background and Overview
5 Recognized Venues
6 Management and Management
7 Familial Homozygous Hypercholesterolemia Hypercholesterolemia: A Guide by the European Atherosclerosis Society (EAS) (2014)
8 Japan Atherosclerosis Society (JAS) Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2017
9 Guidelines for Familial Pediatric Hypercholesterolemia (2017)
Handling algorithm for HOFH
11 Epidemiology and Patient Population
12 Disease 7MM of Homozygous Familial Hypercholesterolemia (HOFH)
For more information about this report, visit https://www.researchandmarkets.com/r/llyrxd
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We bring you the latest data on international and regional markets, key industries, major companies, new products and the latest trends.
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900